抗HIV治療ガイドライン（2023年3月発行）

XI結核合併症例での抗HIV療法

文献

  1. 日本医療研究開発機構感染症実用化研究事業（新興・再興感染症に対する革新的医薬品等開発推進研究事業）「難治性・多剤耐性結核に対する革新的治療法の開発とその提供体制に関する総合的研究」(露口班) 「国立病院機構病院におけるHIV合併多剤耐性結核の実態調査（永井）」2022年.
  2. 日本医療研究開発機構エイズ対策実用化研究事業「ART早期化と長期化に伴う日和見感染症への対処に関する研究」（照屋班）「アンケート結果　日本におけるHIV感染症に伴う日和見合併症の動向−2020年症例分解析−（泉川）」2022年　http://after-art.umin.jp/enq_hiyorimi.html
  3. del Amo J, Moreno S, Bucher HC, et al. Impact of antiretroviral therapy on tuberculosisincidence among HIV-positive patients in high-income countries. Clin Infect Dis. 54:1364-72, 2012.
  4. Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 7:e34156. 2012.
  5. Saito S, Mpofu P, Carter EJ, et al. Declining Tuberculosis Incidence among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012. J Acquir Immune Defic Syndr. 71: e96-e106, 2016.
  6. TEMPRANO ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 373(9):808-22, 2015.
  7. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 373(9):795-807, 2015.
  8. Centers for Disease Control and Prevention: Managing drug interactions in the treatment of HIV-related tuberculosis. June 2013. Available at https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/PDF/tbhiv.pdf
  9. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (Update, Sept 21, 2022). https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines
  10. Guidelines for The Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (Update, Jan 18, 2023). https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
  11. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158:157-61, 1998.
  12. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21:335-41, 2007.
  13. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 379:1915-1925, 2018.
  14. Nahid P, Gonzalez LC, Rudoy I, et al: Treatment outcomes of patients with HIV and tuberculosis. Am. J. Respir. Crit. Care Med.175:1199-1206, 2007.
  15. Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020; 382(10): 893-902. Available at: https://pubmed.ncbi.nlm.nih.gov/32130813/
  16. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 365: 1471-81, 2011.
  17. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 365: 1482-91, 2011.
  18. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 365: 1492-1501, 2011.
  19. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 52:1374-83, 2011.

PAGE TOP